Hepatocyte-based biological therapies are increasingly envisioned for temporary support in acute liver failure and provision of specific-liver functions in liver-based metabolic deficiency. One of the hurdles to develop such therapies is severe shortage of human livers for hepatocyte isolation. To address the issue, we have focused on reversible immortalization of human hepatocytes. Such technology can allow rapid preparation of functional and uniform human hepatocytes. Here we present our strategy to construct transplantable human hepatocyte cell lines.
INTRODUCTION ADVANTAGES OF HEPATOCYTE-BASED BIOLOGICAL THERAPIES Treatment of liver diseases with hepatocyte-based
Cell therapies have several advantages, as shown in cell therapies such as hepatocyte transplantation (HTX) Table 1 . The ultimate goal of cell transplantation would and bioartificial liver (BAL) has significant implications be autologous settings in which the patients' own cells for organ replacement. Compared with whole liver are genetically modified ex vivo and transplanted back transplantation, liver cell transplantation is a technically (5). Cells obtained from a single donor can be used for simple procedure and cells can be cryopreserved for fumultiple patients and cells can be functionally cryopreture use. The application of HTX and BAL is increasserved for the future use. ingly envisioned for temporary metabolic support during acute liver failure and provision of specific liver func-POTENTIAL INDICATIONS OF tions in inherited liver-based metabolic diseases. A ma-HEPATOCYTE-BASED CELL THERAPIES jor limitation to the clinical application of such form of Allogeneic cell transplantation with immunosupprestherapy is the present inability to isolate an adequate sion or tolerization or injection of autologous cells with number of transplantable hepatocytes. Unfortunately, the ex vivo gene transfer can be used for the treatment of number of human livers available for hepatocyte isolainherited liver-based metabolic diseases (4) . Transplantion is limited by competition for their use in wholetation of hepatocytes can be used as a bridge use while organ transplantation. Considering the cost of hepatoawaiting liver transplantation and, in selected cases, can cyte isolation and the need for immediate availability be conducted as a definite therapy (17) . In chronic liver of consistent and functionally uniform cell preparations, disease, HTX and BAL would improve metabolic funchuman hepatocytes cannot be isolated on a scale suffitions and hepatic encephalopathy and could buy time for cient to treat more than a fraction of the patients who finding a suitable donor liver. HTX and BAL could be need HTX or BAL. The use of animal cells would result used as a part of cancer treatment to rescue patients who in additional concerns related to the transmission of inneed curative doses of hepatic irradiation or extended fectious pathogens and immunologic and physiologic insurgery. Transplantation of human hepatocytes into imcompatibilities between donors and humans. This article munodeficient animals allows to create animal models presents an attractive approach to create human hepatofor human hepatocyte-specific infections, including hepcyte cell lines using currently available gene transfer atitis B and C viral infection (12) ( Table 2) . technology. 
CHOICE OF CELLS FOR THERAPIES
Epstein-Barr virus (7). Transduction of normal cells Although human hepatocytes are desirable for cell with the SV40 early region genes, typically by transfectherapies, the use of human cells is severely limited by tion of an expression plasmid, remains a very common the donor organ shortage. Table 3 shows possible alterimmortalization technique (6). We previously transnatives to human hepatocytes for cell-based therapies.
duced human fetal hepatocytes with pSV3neo DNA Human embryonic stem cells (SCs), hepatic SCs, containing both large and small T antigens of the early small hepatocytes, and bone marrow-derived SCs are all region of SV40 and bacterial neomycin phosphotransferpromising (11, 14, (19) (20) (21) (22) . The human liver cell line ase gene. After G418 treatment, one line of the surviving C3A, derived from hepatoblastoma, has been used in a clones, OUMS-29, grew well in the chemically defined bioartificial liver trial in the US (3, 18) . Freshly isolated serum-free medium without any crisis and showed liveror cryopreserved porcine liver cells are also inoculated in specific functions (9). When transplanted into immunoa bioartificial liver device (1, 23) . Entry of abnormal proddeficient mice, OUMS-29 cells were not tumorigenic, ucts from tumor cells into patients' circulation may inbut potential risk of malignant formation of OUMS-29 duce unknown adverse effects, and the use of pig cells cells cannot be precluded in humans. Safeguards, such results in additional concerns related to the transmission as introduction of suicide genes, should be added to imof infectious pathogens, such as porcine endogenous retmortalized cells. roviral infection and immunologic and physiologic incompatibilities between the donor and humans (8,13,25).
Tightly Regulated Immortalized Human Hepatocyte Cell Line Immortalized Hepatocyte Cell Line
Transduction of immortalized hepatocytes with sui-To address such issues, we have made great efforts cide genes would provide a way to eliminate the cells to establish an immortalized human hepatocyte cell line.
after transplantation. Cells modified to express a herpes Such a cell line provides the advantage of uniformity simplex virus-thymidine kinase (HSV-TK) gene become and sterility, grows in unlimited quantity, and is far less sensitive to ganciclovir (GCV) (2) . Thus, we introduced costly than isolated hepatocytes. One approach to creata HSV-TK gene into OUMS-29 cells. The resultant ing a clonal hepatocyte cell line is to transduce primary OUMS-29/TK cells were more than 100 times sensitive hepatocytes with genes from DNA tumor viruses, such to GCV than unmodified parental counterparts and cells as simian virus 40 (SV40), human papillomavirus, and stopped proliferation in the presence of 5 µM GCV. mutant tsA58) and functioned as well as primary hepato-2. Acute liver failure: as a bridge use while awaiting liver transplantation; as definite therapy in selected cases.
Conditionally Immortalized Hepatocyte Cell Line
cytes after transplantation (15) . However, the recipients. 4 . As a part of cancer treatment: to rescue patients who need curative doses of hepatic irradiation.
Reversibly Immortalized Hepatocyte Cell Line The ethical issue of transplanting cells immortalized
